Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing outsourcing by pharmaceutical and biotechnology companies
3.2.1.2 Stringent regulatory landsacep for drug approvals
3.2.1.3 Focus on specialised services by CRO's
3.2.1.4 Risind demand for personalized medicine
3.2.2 Industry pitfalls & challenges
3.2.2.1 Intellectual property rights issues
3.2.2.2 Stringent regulatory policies for animal model use
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Animal Model, 2021 – 2032 ($ Million)
5.1 Key trends
5.2 Rodent-based
5.2.1 Rat models
5.2.2 Mice models
5.2.3 Other rodent models
5.3 Non-rodent-based
Chapter 6 Market Estimates and Forecast, By Service, 2021 – 2032 ($ Million)
6.1 Key trends
6.2 Bioanalysis & DMPK studies
6.3 Toxicity studies
6.3.1 GLP toxicology studies
6.3.2 Non-GLP toxicology studies
6.4 Other services
Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Million)
7.1 Key trends
7.2 Small-molecule drugs
7.3 Large-molecule drugs
7.3.1 Cell & gene therapy
7.3.2 RNA therapy
7.3.3 Other large molecule drugs
Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2032 ($ Million)
8.1 Key trends
8.2 Oncology
8.3 Clinical pharmacology
8.4 Cardiology
8.5 Infectious diseases
8.6 Neurology
8.7 Gastroenterology & hepatology
8.8 Metabolic & endocrine
8.9 Ophthalmology
8.10 Autoimmune / inflammatory conditions
8.11 Other therapeutic areas
Chapter 9 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Million)
9.1 Key trends
9.2 Pharmaceutical & biopharmaceutical companies
9.3 Medical device companies
9.4 Academic & research institutes
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Biocytogen
11.2 Charles River Laboratories International Inc.
11.3 Crown Bioscience
11.4 Evotec
11.5 GemPharmatech
11.6 IQVIA Inc.
11.7 Icon Plc
11.8 Labcorp Drug Development
11.9 Parexel International Corporation
11.10 PsychoGenics Inc.
11.11 Taconic Biosciences, Inc.
